RaySearch Laboratories AB (publ) (RAY B.ST) stock: key figures, P/E, revenue and dividend

Health Care · Sweden · ISIN SE0000135485

Price
176.70 SEK
Market cap
6.06 bn SEK
P/E (2025)
26.57
P/S (2025)
4.51
Dividend yield
2.26 %
Net margin
16.89 %
Return on equity (ROE)
23.04 %
Return on assets (ROA)
11.40 %

RaySearch Laboratories AB (publ) financials

Fiscal year20242025
Revenue1.19 bn SEK1.34 bn SEK
Gross profit1.09 bn SEK1.24 bn SEK
Operating income251.50 m SEK329.60 m SEK
EBIT260.00 m SEK292.00 m SEK
Net income203.00 m SEK227.00 m SEK
Diluted EPS – continuing operations5.94 SEK6.65 SEK

Full history since 2003, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About RaySearch Laboratories AB (publ)

RaySearch Laboratories AB (publ), a medical technology company, provides software solutions for cancer treatment worldwide. It offers RayStation, a treatment planning system for cancer centers; RayCare, an oncology information system for clinics; RayIntelligence, cloud-based oncology analytics system that cancer centers can use to gather, structure and analyze data; and RayCommand, a treatment control system designed to link the treatment machine and the treatment planning and oncology information systems. It also provides µ-RayStation* (Micro-RayStation), a software platform for planning and evaluation in small animal irradiation research; RayPlan, a treatment planning system; DrugLog, which verifies the identity and concentration of compounded injectables before administered to a patient; RayMigrate, allows users to convert Pinnacle patient data to RayStation format and/or to DICOM format; Machine Learning; and Liver Ablation Solutions. The company was founded in 2000 and is headquartered in Stockholm, Sweden.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 06.11.2026. Details in the risk notice.